Enobia is dedicated to treating rare and severe genetic bone-growth disorders for which there are currently no approved drug therapy.

Enobia focuses on the development of therapeutics for the treatment of severe orphan disorders affecting the bone, where no approved therapy exits. These disorders result from a well characterized imbalance in specific enzymes resulting in impaired bone growth.